Raj Naran
Follow
Get notifications in MyBN when activity occurs.
Raj Naran
Raj Naran is an experienced global executive in the Testing, Inspection & Certification (TIC) Industry. He was born and raised in Rhodesia and following compulsory military service, he decided to leave Rhodesia soon after the country was renamed Zimbabwe in 1979. He followed a sibling to the United States where he pursued academic qualifications. Upon graduating in 1984, he commenced employment with several global corporations including Environmental Resources Management (ERM). Through his career, he undertook field based work before progressing to his first laboratory management role in Houston. When ERM sold its' laboratory operations to Core Laboratories, Inc in the US in the early 1990s, Mr Naran transferred with it. After seven years as Laboratory Manager in which he had both laboratory and business development responsibilities, Mr Naran departed in 1999 to commence his own business known as e-Lab Analytical, Inc. Headquartered in Houston. eLab was acquired by ALS in 2007. He currently has residences in Houston and Brisbane, and will split his time between the USA and Australia as required.
Lists and Charts
Total Shareholder Return as at 29/02/24
Rank | Company | 1 yr | 5 yr |
---|---|---|---|
173rd | Cochlear | 60% | 17% |
657th | Mirvac Group | 0% | 1% |
773rd | ALS | -3% | 12% |
1209th | Pact Group Holdings | -33% | -21% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Share Transactions
Revenue
Rank | Company | Revenue | |
---|---|---|---|
89th | ALS | $2,279.2m | |
98th | Pact Group Holdings | $1,952.7m | |
99th | Cochlear | $1,949.6m | |
101st | Mirvac Group | $1,934.0m | |
102nd | AusNet Services | $1,924.5m |
1329 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Show All Lists and Charts
Collapse All Lists and Charts
Related Information
Positions - Previous
Position | Company | Year | Company's current rank |
---|---|---|---|
Managing Director, Chief Executive | ALS | 2017 - 2023 | 89 |
Group General Manager, Life Sciences Division | ALS | 2007 - 2017 | 89 |
Directors Interests
Company | Date | Transaction type | Number of shares | Price per share | Transaction value | Nature of change |
---|---|---|---|---|---|---|
ALS | 07 Jul 2022 | Other | 123,359 | $10.63 | $1,311,306 | OtherConversion of securities: Average price/Estimatedvalue based on the number of PerformanceRights.257,179 Performance Rights |
ALS | 07 Jul 2022 | Sold | 130,000 | $10.23 | $1,330,400 | OtherAs advised by the company: Sale of Ordinary Shares to cover tax liabilityfrom vesting of shares under Company's LTIPlan. |
ALS | 07 Jul 2022 | Bought | 123,359 | $10.63 | $1,311,306 | OtherConversion of securities: Average price/Estimatedvalue based on the number of PerformanceRights. |
ALS | 13 Jan 2022 | Sold | 30,000 | $12.86 | $385,933 | OtherAs advised by the company: Sale of Ordinary shares to cover tax liability from vesting of shares under Company's LTI Plan. |
ALS | 01 Sep 2021 | Sold | 79,500 | $12.37 | $983,647 | OtherAs advised by the company: Sale of Ordinary shares to cover tax liability from vesting of shares under Company's LTI Plan. |
Powered by Morningstar ®
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX